Shares of China Shineway Pharmaceutical Group (SHINEWAY PHARM) plunged 5.09% in intraday trading, extending its recent losses following the release of disappointing full-year 2024 financial results. The pharmaceutical company's performance fell short of analyst expectations, sparking concerns among investors.

According to the released figures, SHINEWAY PHARM reported a revenue of CN¥3.78 billion for the full year 2024, representing a 16% decrease from the previous year. The company's net income also declined by 13% to CN¥840.1 million. Earnings per share (EPS) fell to CN¥1.11, down from CN¥1.28 in 2023. Both revenue and EPS missed analyst estimates by 6.8% and 11% respectively, contributing to the negative market reaction.

Despite the current setback, analysts forecast a 15% per annum revenue growth for SHINEWAY PHARM over the next two years, outpacing the 8.6% growth projected for the Hong Kong Pharmaceuticals industry. However, investors should note that the company is showing a warning sign in investment analysis, suggesting potential risks ahead. With three products in Phase III clinical trials, the market will be closely watching SHINEWAY PHARM's pipeline developments for potential catalysts that could reverse the current downtrend.